Although we found activity of the combination therapy in the adagrasib resistant SW1573 model, this does not clarify that the patients with KRAS G12C mutant NSCLC brain metastasis that are resistant to KRAS G12C inhibitors are more likely to benefit from the combination therapy. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.